The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3 Randomized, ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate for the treatment of Sjögren’s Syndrome, a serious autoimmune disease.

Considering that IgG4-related syndrome also affects the parotid glands frequently, this overlap in symptoms further supports biopsy as a method to ensure the correct diagnosis of Sjögren's ...